This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

ChinaBio® Partnering Forum
Kerry Hotel Pudong
September 10–11, 2024 | Shanghai, ChinaSeptember 16–17, 2024 | Virtual

Dan Wang
Regional Head at Johnson & Johnson Innovation, Asia Pacific
Speaker

Profile

Dan Wang, MD, DBA, MPH is the Head of Johnson & Johnson Innovation in Asia Pacific, responsible for managing a portfolio of coinvestments and deal execution spanning across both business sectors of medical devices and pharmaceutical and expanding external networks within the innovation ecosystem in the region. On this role, she has led the Asia Pacific Innovation Center in completing multiple research collaboration, co-development, license in and equity investment collaborations in China, Japan, South Korea, Singapore to enhance the global portfolio and pipeline of Johnson & Johnson.

Dan has over 20 years experience in the life sciences sector. Prior to joining Johnson & Johnson Innovation, Dan worked with Becton Dickinson (BD) as head of Strategic Innovation, R&D in China and as Worldwide Clinical Development Lead, China e-Capital Corporation as Executive Director in charge of healthcare deal transactions, Express Scripts as Chief Medical Officer in China, Johnson & Johnson as head of Medical Affairs in Janssen China, and resident in the dermatology department of Peking University 1st Hospital. Dan has a strong track record in strategic innovation, identifying new product opportunities and external partnerships.

Dan holds MD and MSc degrees from Peking University, an MBA from Goizueta Business School, an MPH from Rollins School of Public Health at Emory University, Atlanta and Doctor of Business Administration (DBA) from Hong Kong University.

Agenda Sessions

  • Keynote panel: Achieving renewed success in China thorough increased collaboration, enhanced asset valuation and international reach

    09:30